Protalix BioTherapeutics (PLX) Receivables - Other (2010 - 2019)
Protalix BioTherapeutics (PLX) posted Receivables - Other of $26000.0 for Q4 2019, down 99.0% on a QoQ basis from $2.6 million in Q1 2014.
Powered by 
Analysis
Protalix BioTherapeutics (PLX) Receivables - Other (2010 - 2019) Analysis & Trends
Protalix BioTherapeutics has reported Receivables - Other for 6 years, with the latest figure at $26000.0 in Q4 2019.
- On a quarterly basis, Receivables - Other changed N/A year-over-year to $26000.0 in Q4 2019; TTM through Dec 2019 was $26000.0, a N/A change from a year earlier, with the FY2019 full-year figure at $26000.0, changed N/A from the prior year.
- Receivables - Other was $26000.0 for Q4 2019 at Protalix BioTherapeutics, down from $2.6 million in the prior quarter.
- The five-year high for Receivables - Other was $26000.0 in Q4 2019, with the low at $26000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Protalix BioTherapeutics | 218.36 Mn | 177.71 Mn | 12.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 26,000.00 |
| Mar 31, 2014 | 2.61 Mn |
| Dec 31, 2013 | 1.46 Mn |
| Sep 30, 2013 | 4.17 Mn |
| Jun 30, 2013 | 3.59 Mn |
| Mar 31, 2013 | 3.55 Mn |
| Dec 31, 2012 | 3.69 Mn |
| Sep 30, 2012 | 3.28 Mn |
| Jun 30, 2012 | 4.05 Mn |
| Mar 31, 2012 | 3.15 Mn |
| Dec 31, 2011 | 3.84 Mn |
| Sep 30, 2011 | 3.02 Mn |
| Jun 30, 2011 | 4.88 Mn |
| Dec 31, 2010 | 2.23 Mn |